{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:18:31Z","timestamp":1787671111445,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.sapharm.2026.05.009","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:26:57Z","timestamp":1779380817000},"page":"927-935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world pharmacovigilance analysis of drug-induced liver injury in 18-65\u00a0years: Based on the FDA adverse event reporting system (FAERS)"],"prefix":"10.1016","volume":"22","author":[{"given":"Xinlong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-9453","authenticated-orcid":false,"given":"Kaijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.sapharm.2026.05.009_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd1750","article-title":"Idiosyncratic drug hepatotoxicity","volume":"4","author":"Kaplowitz","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.sapharm.2026.05.009_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.sapharm.2026.05.009_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"10.1016\/j.sapharm.2026.05.009_bib4","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in mainland China","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.sapharm.2026.05.009_bib5","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s12072-024-10679-1","article-title":"Age-related differences in drug-induced liver injury: a retrospective single-center study from a large liver disease specialty hospital in China, 2002\u20132022","volume":"18","author":"Yu","year":"2024","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.sapharm.2026.05.009_bib6","article-title":"Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study","volume":"152","author":"P","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.sapharm.2026.05.009_bib7","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1038\/s41598-025-89272-x","article-title":"Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database","volume":"15","author":"Zhu","year":"2025","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.sapharm.2026.05.009_bib8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bcp.16318","article-title":"Drug-induced liver injury associated with pretomanid, bedaquiline, and linezolid: insights from FAERS database analysis","volume":"91","author":"He","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.sapharm.2026.05.009_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2025.03.023","article-title":"Drugs associated with floppy iris syndrome: a real-world population-based study","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.sapharm.2026.05.009_bib10","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.apsb.2021.05.028","article-title":"Hepatotoxicity reports in the FDA adverse event reporting system database: a comparison of drugs that cause injury via mitochondrial or other mechanisms","volume":"11","author":"Rana","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"10.1016\/j.sapharm.2026.05.009_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/03602530902722679","article-title":"Pharmacokinetics and drug metabolism in the elderly","volume":"41","author":"Klotz","year":"2009","journal-title":"Drug Metab Rev"},{"issue":"2","key":"10.1016\/j.sapharm.2026.05.009_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.50.2.259","article-title":"Developmental aspects of human hepatic drug glucuronidation in young children and adults","volume":"50","author":"Strassburg","year":"2002","journal-title":"Gut"},{"issue":"9\u201310","key":"10.1016\/j.sapharm.2026.05.009_bib13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.drudis.2006.03.002","article-title":"New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology","volume":"11","author":"Stevens","year":"2006","journal-title":"Drug Discov Today"},{"issue":"9","key":"10.1016\/j.sapharm.2026.05.009_bib14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S2468-1253(20)30006-6","article-title":"Drug-induced liver injury in older people","volume":"5","author":"Lucena","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.sapharm.2026.05.009_bib15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1365-2125.2012.04446.x","article-title":"Predicted metabolic drug clearance with increasing adult age","volume":"75","author":"Polasek","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.sapharm.2026.05.009_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-025-01051-6","article-title":"Epidemiology of drug-related liver injury among the elderly: a systematic review and meta-analysis of incidence, and risk factors","volume":"27","author":"Fan","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.sapharm.2026.05.009_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fmed.2018.00167","article-title":"Retrospective study of reported adverse events due to complementary health products in Singapore from 2010 to 2016","volume":"5","author":"Xu","year":"2018","journal-title":"Front Med"},{"issue":"4","key":"10.1016\/j.sapharm.2026.05.009_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40264-023-01390-5","article-title":"Drug-induced liver injury in the elderly: consensus statements and recommendations from the IQ-DILI initiative","volume":"47","author":"Cohen","year":"2024","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.sapharm.2026.05.009_bib19","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.sapharm.2026.05.009_bib20","article-title":"Drug-induced liver injury in children: a nationwide cohort study from China","volume":"6","author":"Lai","year":"2024","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.sapharm.2026.05.009_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.sapharm.2026.05.009_bib22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00431-025-06068-x","article-title":"Evaluation of drug-related anaphylaxis in children: multi-center study","volume":"184","author":"Metbulut","year":"2025","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.sapharm.2026.05.009_bib23","article-title":"Combining apatinib and oxaliplatin remodels the immunosuppressive tumor microenvironment and sensitizes desert-type gastric cancer to immunotherapy","author":"Lin","year":"2025","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.sapharm.2026.05.009_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0289746","article-title":"Assessment of liver function tests of women taking hormonal contraceptives at university of gondar comprehensive specialized hospital and family guidance association of gondar (FGAE), 2022; a comparative cross-sectional study","volume":"18","author":"Chane","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.sapharm.2026.05.009_bib25","doi-asserted-by":"crossref","unstructured":"M\u00e1rquez-Friedrichs F, Nolly MB, Ferreyra A, et al. Shifts in bla genes and class 1 integron prevalence in beta-lactamase-producing bacteria before and after the COVID-19 pandemic in Mendoza, Argentina. Microbiol Spectr. 13(8):e02771-24. doi:10.1128\/spectrum.02771-24.","DOI":"10.1128\/spectrum.02771-24"},{"issue":"12","key":"10.1016\/j.sapharm.2026.05.009_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70200","article-title":"Human metapneumovirus circulation and seasonality on a global scale, 2016-2025: changes in patterns and epidemic timing in the Pre- versus Post-COVID-19 era","volume":"19","author":"Castellana","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.sapharm.2026.05.009_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1378090","article-title":"CDK4\/6 inhibitors in drug-induced liver injury: a pharmacovigilance study of the FAERS database and analysis of the drug-gene interaction network","volume":"15","author":"She","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.sapharm.2026.05.009_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40800-015-0018-0","article-title":"Enoxaparin-induced liver injury: case report and review of the literature and FDA adverse event reporting system (FAERS)","volume":"2","author":"Hahn","year":"2015","journal-title":"Drug Saf Case Rep"},{"key":"10.1016\/j.sapharm.2026.05.009_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1479625","article-title":"Hepatotoxicity of antipsychotics: an exploratory pharmacoepidemiologic and pharmacodynamic study integrating FAERS data and in vitro receptor-binding affinities","volume":"15","author":"Zeiss","year":"2024","journal-title":"Front Psychiatr"},{"issue":"8","key":"10.1016\/j.sapharm.2026.05.009_bib30","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1007\/s10620-016-4121-6","article-title":"Amoxicillin-clavulanate-induced liver injury","volume":"61","author":"deLemos","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"6\u20137","key":"10.1016\/j.sapharm.2026.05.009_bib31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/00365521.2017.1291719","article-title":"Drug-induced liver injury due to antibiotics","volume":"52","author":"Bj\u00f6rnsson","year":"2017","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"10.1016\/j.sapharm.2026.05.009_bib32","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sapharm.2026.05.009_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1437681","article-title":"Dose\u2013response relationship of serum ferritin and dietary iron intake with metabolic syndrome and non-alcoholic fatty liver disease incidence: a systematic review and meta-analysis","volume":"11","author":"Yu","year":"2024","journal-title":"Front Nutr"},{"key":"10.1016\/j.sapharm.2026.05.009_bib34","article-title":"Profiles and influencing factors of pulmonary fibrosis associated with biologic and conventional disease-modifying antirheumatic drugs for autoimmune diseases: a disproportionality study based on FAERS and VigiAccess","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.sapharm.2026.05.009_bib35","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.immuni.2023.10.008","article-title":"Sex hormone signaling and regulation of immune function","volume":"56","author":"Hoffmann","year":"2023","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.sapharm.2026.05.009_bib36","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/jac\/dkw054","article-title":"Gender differences in antibiotic prescribing in the community: a systematic review and meta-analysis","volume":"71","author":"Schr\u00f6der","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.sapharm.2026.05.009_bib37","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s40263-019-00677-5","article-title":"Ischemic and thrombotic events associated with concomitant Xa-inhibiting direct oral anticoagulants and antiepileptic drugs: analysis of the FDA adverse event reporting System (FAERS)","volume":"33","author":"Perlman","year":"2019","journal-title":"CNS Drugs"},{"issue":"6692","key":"10.1016\/j.sapharm.2026.05.009_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/science.adk6200","article-title":"Sexual dimorphism in skin immunity is mediated by an androgen-ILC2-dendritic cell axis","volume":"384","author":"Chi","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.sapharm.2026.05.009_bib39","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1186\/s12879-022-07896-0","article-title":"Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019","volume":"22","author":"Gao","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"9","key":"10.1016\/j.sapharm.2026.05.009_bib40","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00228-019-02691-4","article-title":"Interaction between paracetamol and lamotrigine: new insights from the FDA adverse event reporting system (FAERS) database","volume":"75","author":"Carnovale","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.sapharm.2026.05.009_bib41","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40620-021-01191-y","article-title":"Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems","volume":"35","author":"Gatti","year":"2022","journal-title":"J Nephrol"},{"issue":"6","key":"10.1016\/j.sapharm.2026.05.009_bib42","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/liv.15892","article-title":"Drug\u2010induced liver injury ascribed to non\u2010steroidal anti\u2010inflammatory drugs in the \u2014update with genetic correlations","volume":"44","author":"Bonkovsky","year":"2024","journal-title":"Liver Int"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741126001117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741126001117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:29:18Z","timestamp":1785353358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741126001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1551741126001117"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2026.05.009","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world pharmacovigilance analysis of drug-induced liver injury in 18-65\u00a0years: Based on the FDA adverse event reporting system (FAERS)","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2026.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}